Transformative power of the generative AI (Gen AI) will probably reshape the health care industry over time, and organizations are starting to act. In our T1 2024 survey, more than 70% of the respondents of health care organizations – including payers, providers, health services and technology (THST) – depending on whether they continue or have already implemented GEN AI capabilities (see the sidebar, “research methodology”).
The T1 2024 investigation, which included 100 American leaders, was carried out in March and intervenes after the investigation of the fourth quarter of 2023 with 100 American leaders, which was conducted in December 2023. While we examine the answers through these populations in the two investigations, some themes emerge.
After Gen I entered the world scene at the end of 2022, we now see the health care industry by more actively considering its strategy for using this technology. Although these surveys are small and do not represent an exhaustive vision of all stakeholders in health care, they are supposed to provide early information on the potential of the AI generation. As the results of the survey show, many health care leaders have started to pursue plans to adopt technology more widely, which has partly been rendered by strategic partnerships. Given the complexities concerning technical implementation and integration into a company, interfunctional collaborations allow organizations to provide external talents while taking advantage of the construction of flexible and customizable GEN AI solutions, compared to the purchase of standard solutions. However, depending on the technological maturity of an organization or the way in which a use case is simple, the purchase of GEN AI products accessible to the public can offer a viable alternative to exploit the value of technology. Direct purchases can make sense, especially for functional uses that have matured more quickly, as for customer service applications.
As the deployment of General AI progresses, many leaders interviewed share that their organizations focus on the initial use of this technology to support clinically adjacent applications, with clinical and administrative efficiency and the commitment of patients / members of implementation as areas that hold the most time from General AI. However, while organizations develop solid skills in governance and risk management, we also expect an additional concentration on basic clinical applications, further improving the overall experience of the patient / members.
Despite the promise of the AI generation, the path to responsible use is not without obstacle. Risks such as inaccurate results and biases are particularly essential in health care when dealing with patients. Given that organizations introduce this new technology into workflows, the risks of AI seem to be essential for many heads of health interviewed. The risks will have to be proactively attenuated, which begins with a concerted emphasis on the establishment of governance process, executives and railing to anticipate, identify and manage risks. In doing so, health care organizations can use GEN IA to help guarantee that the advantages are carried out online with regulatory expectations without compromising ethics or safety.